The Pharmagellan Guide to Analyzing Biotech Clinical Trials
Frank S. David, MD, PhD, is the founder and managing director of the biotech consultancy Pharmagellan, where he assists firms and investors in unlocking the financial and strategic potential of creative R&D.
If you work in or around biotech, you should be familiar with clinical trial findings. But what if you don't have any experience with research design or biostatistics? When confronted with a journal article, press release, or investor presentation, you may feel out of your element.
Among the best books on biostatistics, The Pharmagellan Guide to Analyzing Biotech Clinical Trials is a thorough primer designed to assist non-experts in evaluating clinical trials of novel treatments.
- A structured path for evaluating the primary components of a biotech study that is either planned or finished.
- Over 100 real-world examples are used to demonstrate clear explanations of the most popular ideas and words in clinical trials.
- P values, sample size calculations, and Kaplan-Meier curves are all covered in depth in plain English for non-statisticians.
- Tips on assessing positive and negative outcomes, comprehending popular figures and tables, and spotting red flags in press releases.
If you are a biotech executive, investor, adviser, or entrepreneur, or aspire to be one, this manual will provide you with the foundation you need to confidently interpret clinical trials.
Author: Frank S. David MD PhD
Link to buy: https://www.amazon.com/Pharmagellan-Analyzing-Biotech-Clinical-Trials/dp/0998407526/
Ratings: 4.5 out of 5 stars (from 16 reviews)
Best Sellers Rank: #105,479 in Books
#9 in Biostatistics (Books)
#37 in Pharmaceutical & Biotechnology Industry (Books)
